In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Adma Biologics Inc (NASDAQ: ADMA) closed at $18.24 down -0.65% from its previous closing price of $18.36. In other words, the price has decreased by -$0.65 from its previous closing price. On the day, 1.94 million shares were traded. ADMA stock price reached its highest trading level at $18.4 during the session, while it also had its lowest trading level at $18.17.
Ratios:
For a deeper understanding of Adma Biologics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 70.72 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 106.58. For the most recent quarter (mrq), Quick Ratio is recorded 3.65 and its Current Ratio is at 7.13. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.18.
On October 13, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $5.
Raymond James Upgraded its Outperform to Strong Buy on November 11, 2021, while the target price for the stock was maintained at $5.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 15 ’25 when Grossman Adam S sold 21,000 shares for $19.79 per share. The transaction valued at 415,590 led to the insider holds 2,007,850 shares of the business.
Grossman Adam S sold 21,000 shares of ADMA for $336,000 on Nov 19 ’25. The President and CEO now owns 2,013,850 shares after completing the transaction at $16.00 per share. On Oct 24 ’25, another insider, Grossman Adam S, who serves as the President and CEO of the company, sold 21,000 shares for $16.00 each. As a result, the insider received 336,000 and left with 2,019,850 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADMA now has a Market Capitalization of 4352624128 and an Enterprise Value of 4362817024. As of this moment, Adma’s Price-to-Earnings (P/E) ratio for their current fiscal year is 21.42, and their Forward P/E ratio for the next fiscal year is 20.73. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.60. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.89 while its Price-to-Book (P/B) ratio in mrq is 10.08. Its current Enterprise Value per Revenue stands at 8.93 whereas that against EBITDA is 24.929.
Stock Price History:
The Beta on a monthly basis for ADMA is 0.46, which has changed by -0.010845959 over the last 52 weeks, in comparison to a change of 0.15196204 over the same period for the S&P500. Over the past 52 weeks, ADMA has reached a high of $25.67, while it has fallen to a 52-week low of $13.50. The 50-Day Moving Average of the stock is 4.32%, while the 200-Day Moving Average is calculated to be 0.24%.
Shares Statistics:
For the past three months, ADMA has traded an average of 3.21M shares per day and 1860290 over the past ten days. A total of 238.33M shares are outstanding, with a floating share count of 229.92M. Insiders hold about 3.40% of the company’s shares, while institutions hold 92.78% stake in the company. Shares short for ADMA as of 1765756800 were 18829424 with a Short Ratio of 5.87, compared to 1763078400 on 18629225. Therefore, it implies a Short% of Shares Outstanding of 18829424 and a Short% of Float of 9.7200006.
Earnings Estimates
. The current rating of Adma Biologics Inc (ADMA) reflects the combined expertise of 1.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.2, with high estimates of $0.2 and low estimates of $0.2.
Analysts are recommending an EPS of between $0.6 and $0.6 for the fiscal current year, implying an average EPS of $0.6. EPS for the following year is $0.94, with 1.0 analysts recommending between $0.94 and $0.94.
Revenue Estimates
A total of 2 analysts believe the company’s revenue will be $139.85M this quarter.It ranges from a high estimate of $140.3M to a low estimate of $139.4M. As of. The current estimate, Adma Biologics Inc’s year-ago sales were $117.55MFor the next quarter, 2 analysts are estimating revenue of $145.35M. There is a high estimate of $149M for the next quarter, whereas the lowest estimate is $141.7M.
A total of 2 analysts have provided revenue estimates for ADMA’s current fiscal year. The highest revenue estimate was $511.3M, while the lowest revenue estimate was $510.4M, resulting in an average revenue estimate of $510.85M. In the same quarter a year ago, actual revenue was $426.45MBased on 2 analysts’ estimates, the company’s revenue will be $631.85M in the next fiscal year. The high estimate is $632.5M and the low estimate is $631.2M.
